What it is
Misoprostol (brand name Cytotec) is a synthetic prostaglandin. In induction it's used off-label but very commonly, given in small doses every few hours until the cervix ripens or labor starts. It is inexpensive and effective, but the dose can't be removed once given — a key difference from Cervidil.
Evidence review links
Each link opens the full review on the publisher's site in a new tab.
Possible benefits
- Effective at ripening the cervix and often triggers labor without needing PitocinReview sources ↓
- Inexpensive and widely availableReview sources ↓
- Can shorten total induction time compared with Pitocin aloneReview sources ↓
Possible risks
- Cannot be removed once given — if contractions get too strong, treatment is supportiveReview sources ↓
- Higher risk of tachysystole (contractions too strong / close together) than Cervidil or FoleyReview sources ↓
- NOT recommended for anyone with a prior cesarean (risk of uterine rupture)Review sources ↓
- Use is off-label in the U.S., though endorsed by ACOG for inductionReview sources ↓
Alternatives
- Cervidil (dinoprostone insert) — removable prostaglandinReview sources ↓
- Foley/Cook balloon — mechanical, no medicationReview sources ↓
- Pitocin alone if the cervix is already favorableReview sources ↓
Current evidence
ACOG's induction bulletin explicitly supports misoprostol as a first-line cervical ripening agent and explicitly warns against its use in people with a prior uterine scar. Evidence Based Birth's due-date induction and induction-trends resources discuss how cervical ripening methods fit into the larger induction sequence. See: https://evidencebasedbirth.com/evidence-on-inducing-labor-for-going-past-your-due-date/
Where the evidence is clear · where people may choose differently
For most topics, guidelines from ACOG, WHO, and other major bodies broadly agree on the core safety points (when to act in an emergency, informed-consent standards, monitoring baselines). Where reasonable people — and even guidelines — differ tends to be around thresholds (when to start or stop something), preferences (comfort, environment, support), and values (how you weigh small risks against benefits). Use the questions below to explore those pieces with your care team.
Educational only. Your care team can help you weigh what applies to your specific situation.
Questions to ask your care team
- ?Why misoprostol here instead of Cervidil or a Foley?
- ?What dose and how often will you re-dose?
- ?How will you respond if I get tachysystole?
- ?Is misoprostol safe given my birth history?
Universal questions (works for any decision)
A short BRAIN-style set you can bring to any conversation about interventions, monitoring, or care decisions.
- ?Why are you recommending this now — is it urgent, routine, or optional?
- ?What happens if we wait an hour (or longer) before deciding?
- ?What signs would tell us this is working — or that we need to change course?
- ?What are the alternatives, including doing nothing?
- ?What would you recommend if this were your family?
- ?What would change your recommendation?
Sources & provenance
Tap a source to open the original guideline or review in a new tab.
- ACOG Practice Bulletin 107: Induction of Labor — ACOG
- Evidence on: Inducing at 41 Weeks or Later — Evidence Based Birth
Written in plain language from general guidance published by the listed organizations. No verbatim excerpts; editors should re-verify wording and citations against current source versions before publish.
Last reviewed: 2026-07-02
Further reading — canonical references
Read the source material directly. Each link opens the publisher's own current guidance in a new tab — cross-check what we summarize against what they say.
Tier 1 · Clinical guidelines
Tier 2 · Systematic reviews
Educational only. Guidelines evolve — the linked publisher pages will reflect newer guidance than any static snapshot.
Version history — v1.0.0
v1.0.0 · 2026-07-02 · LlaMamma editors
Initial misoprostol/Cytotec topic added with ACOG and Evidence Based Birth induction links.
Sources: ACOG Practice Bulletin 107; Evidence Based Birth due-date induction review
New guidance from ACOG, WHO, Evidence Based Birth, or other listed sources is recorded here and can be updated remotely without a new app release.